Qu Biologics Inc

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohns disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohns disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by...

Biotechnology,ulcerative colitis,crohn's disease,arthritis,cancer,autoimmune diseases,autoimmune disorders,inflammatory bowel disease,ibd,site specific immunomodulators,immunotherapies,investigational drug,pharmaceuticals,research,inflammation,biotech,clinical trials,innate immunity,covid,and biologics

Qu biologics inc operates in the Biotechnology research industry.

Qu biologics inc's revenue is 1m - 10m

Qu biologics inc has 11 - 50 employees.